'Game-changing' HIV protection jab approved in England and Wales
Summary
The NHS in England and Wales will start offering cabotegravir, an injection to prevent HIV, providing a new option instead of daily pills. This treatment aims to reduce new HIV cases by 2030 and is available for those who find taking pills difficult. Patients at high risk of HIV and eligible for PrEP can receive this injection, which lasts for two months.Key Facts
- Cabotegravir is an injection approved for preventing HIV in England and Wales.
- It is an alternative to daily pills for pre-exposure prophylaxis (PrEP).
- Cabotegravir requires a shot every two months, six times a year.
- The NHS negotiated a discount on the injection, initially priced at around £7,000 per person per year.
- The injection will be offered to around 1,000 high-risk individuals who struggle with taking oral PrEP.
- The injection aims to help end new HIV cases by 2030 in the UK.
- Access to PrEP varies with the highest uptake among certain male groups and lower among black African heterosexual women and men.
- There is ongoing HIV testing in hospital A&E departments in high-prevalence areas in England.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.